ORPHA:370026
Acute myeloid leukemia with t(8;16)(p11;p13) translocation
Also known as: AML with t(8;16)(p11;p13) translocation
Publications
2
8th percentile
Trials
0
Interventional, condition-specific
Researchers
24
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A distinct form of Acute myeloid leukemia (AML) in which this chromosomal anomaly is found de novo or in therapy-related AML cases, and is characterized by frequent extramedullary involvement (mainly , , lymphadenopathies, cutaneous infiltration, but also gum, bone, central nervous system, testicles involvement), severe coagulation disorder (disseminated intravascular coagulopathy or primary fibrinolysis) and poor prognosis. Morphologically, a blast population with a myelomonocytic stage of differentiation is observed.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018256
- UMLS:C4511003
- NCIT:C200421
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2 matched papers (1 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 2487 for broader category acute myeloid leukemia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
2
2 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
2 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1 in the last 10 years · high confidence · 8th percentile (publications denominator)
Phrase hits: 2 · MeSH hits: 0
Who's working on it?
24
Distinct author names in 2 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Aguilar JL1 paper · 2004Papers in Europe PMC
- 02Aqil B1 paper · 2022
Division of Hematopathology, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Papers in Europe PMC - 03Aymerich M1 paper · 2004Papers in Europe PMC
- 04Camós M1 paper · 2004Papers in Europe PMC
- 05Campo E1 paper · 2004Papers in Europe PMC
- 06Carrió A1 paper · 2004Papers in Europe PMC
- 07Colomer D1 paper · 2004Papers in Europe PMC
- 08Costa D1 paper · 2004Papers in Europe PMC
- 09Domingo A1 paper · 2004Papers in Europe PMC
- 10Duncavage EJ1 paper · 2022
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 2,487 trials are registered for acute myeloid leukemia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
2,487 interventional trials matched acute myeloid leukemia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: acute myeloid leukemia
2,487
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07392814·NOT YET RECRUITING·Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia
Conditions: Leukemia Acute Myeloid - AML·Matched via name phrase
- NCT06551584·RECRUITING·Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Conditions: Acute Myeloid Leukemia · Acute Lymphoid Leukemia · Mixed Phenotype Acute Leukemia · Myelodysplastic Syndromes·Matched via name phrase
- NCT06812104·RECRUITING·Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
Conditions: Relapsed or Refractory AML and Other Hematologic Malignancies·Matched via name phrase
- NCT06281847·NOT YET RECRUITING·An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
Conditions: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory·Matched via name phrase
- NCT06138587·RECRUITING·Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Conditions: Acute Myeloid Leukemia · Leukemia · Leukemia, Myeloid · Myelodysplastic Syndromes·Matched via name phrase
- NCT05506332·RECRUITING·Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory·Matched via name phrase
- NCT03507842·ENROLLING BY INVITATION·A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
Conditions: Acute Myeloid Leukemia·Matched via name phrase
- NCT06504459·RECRUITING·Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Conditions: Acute Monocytic Leukemia · Acute Myeloid Leukemia·Matched via name phrase
- NCT06820268·RECRUITING·A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
Conditions: B-cell Lymphoma · Acute Myeloid Leukemia · Myelodysplastic Syndrome·Matched via name phrase
- NCT05564390·RECRUITING·MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Conditions: Acute Myeloid Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm · Acute Myeloid Leukemia Post Cytotoxic Therapy · Acute Myeloid Leukemia, Myelodysplasia-Related·Matched via name phrase
- NCT05947344·RECRUITING·A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
Conditions: AML, Adult·Matched via name phrase
- NCT07302776·RECRUITING·TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Conditions: GVHD · Hematopoietic Cell Transplantation (HCT) · Acute Myeloid Leukemia (AML) · Myelodysplastic Syndromes·Matched via name phrase
- NCT07106749·RECRUITING·CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Conditions: Acute Myeloid Leukemia · B Acute Lymphoblastic Leukemia/Lymphoma·Matched via name phrase
- NCT06252584·NOT YET RECRUITING·Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
Conditions: Acute Myeloid Leukemia, Adult·Matched via name phrase
- NCT05772273·RECRUITING·PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Conditions: Acute Myeloid Leukemia·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Acute myeloid leukemia with t(8;16)(p11;p13) translocation — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acute myeloid leukemia with t(8;16)(p11;p13) translocation" OR "AML with t(8;16)(p11;p13) translocation"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acute myeloid leukemia with t(8;16)(p11;p13) translocation" OR "AML with t(8;16)(p11;p13) translocation"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"acute myeloid leukemia"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T14:53:11.175Z
